Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Metabolic Syndrome
NCT00111956Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Apr 2004
- Primary completion
- May 2005
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic syndrome comparing Etanercept with Placebo (2 arms). Primary endpoint: C-reactive protein at 25 days. Started Apr 2004; status: completed.
02
Drugs
etanercept
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT00111956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111956.